Invention Grant
- Patent Title: Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
-
Application No.: US15812142Application Date: 2017-11-14
-
Publication No.: US10093656B2Publication Date: 2018-10-09
- Inventor: Charles Z. Ding , Shuhui Chen , Baoping Zhao , Xile Liu , Linxia Xiao , Chao Ding , Fei Wang , Jian Li
- Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD
- Applicant Address: CN Nanjing
- Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD
- Current Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD
- Current Assignee Address: CN Nanjing
- Agency: Harness, Dickey & Pierce, P.L.C.
- Priority: CN201510213398 20150429
- Main IPC: C07D403/04
- IPC: C07D403/04 ; C07D487/04 ; C07D471/04 ; C07D401/04
Abstract:
Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
Public/Granted literature
- US20180072704A1 Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor Public/Granted day:2018-03-15
Information query
